Title Image

R&D

HND-020
03.Tascenso ODT
Indication Multiple Sclerosis
Status Tentative Approval Granted on December 18, 2021.
Product Advantages Orally disintegrating tablet format is generally known to be of particular relevance to patients with swallowing difficulties. Handa ODT product is relevant to patients who have some level of dysphagia, patients who need to switch therapies due to efficacy or tolerability issues with current therapy, and patients who prefer ODT administration.
Potential Market Currently, there are no orally disintegrating tablet for Multiple Sclerosis-targeted on the market.